SI0966448T1 - Pyrazine compounds - Google Patents

Pyrazine compounds

Info

Publication number
SI0966448T1
SI0966448T1 SI9830578T SI9830578T SI0966448T1 SI 0966448 T1 SI0966448 T1 SI 0966448T1 SI 9830578 T SI9830578 T SI 9830578T SI 9830578 T SI9830578 T SI 9830578T SI 0966448 T1 SI0966448 T1 SI 0966448T1
Authority
SI
Slovenia
Prior art keywords
pyrazine compounds
pyrazine
compounds
Prior art date
Application number
SI9830578T
Other languages
English (en)
Slovenian (sl)
Inventor
Brian Cox
Malcolm Stuart Nobbs
Gita Punjabhai Shah
Dean David Edney
Michael Simon Loft
Original Assignee
Glaxo Group Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9704275.8A external-priority patent/GB9704275D0/en
Priority claimed from GBGB9708183.0A external-priority patent/GB9708183D0/en
Application filed by Glaxo Group Limited filed Critical Glaxo Group Limited
Publication of SI0966448T1 publication Critical patent/SI0966448T1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/20—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D241/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Detergent Compositions (AREA)
SI9830578T 1997-03-01 1998-02-26 Pyrazine compounds SI0966448T1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB9704275.8A GB9704275D0 (en) 1997-03-01 1997-03-01 Pharmacologically active compound
GBGB9708183.0A GB9708183D0 (en) 1997-04-23 1997-04-23 Pharmacologically active compound
PCT/EP1998/001077 WO1998038174A1 (en) 1997-03-01 1998-02-26 Pyrazine compounds
EP98913592A EP0966448B1 (en) 1997-03-01 1998-02-26 Pyrazine compounds

Publications (1)

Publication Number Publication Date
SI0966448T1 true SI0966448T1 (en) 2004-04-30

Family

ID=26311097

Family Applications (1)

Application Number Title Priority Date Filing Date
SI9830578T SI0966448T1 (en) 1997-03-01 1998-02-26 Pyrazine compounds

Country Status (46)

Country Link
US (2) US6255307B1 (bg)
EP (1) EP0966448B1 (bg)
JP (1) JP3369189B2 (bg)
KR (1) KR100544263B1 (bg)
CN (1) CN1105111C (bg)
AP (1) AP9901632A0 (bg)
AR (1) AR011174A1 (bg)
AT (1) ATE251143T1 (bg)
AU (1) AU732915B2 (bg)
BG (1) BG103723A (bg)
BR (1) BR9807814B1 (bg)
CA (1) CA2282585C (bg)
CO (1) CO4950513A1 (bg)
CZ (1) CZ295618B6 (bg)
DE (1) DE69818643T2 (bg)
DK (1) DK0966448T3 (bg)
EA (1) EA002102B1 (bg)
EE (1) EE9900376A (bg)
ES (1) ES2205469T3 (bg)
GE (1) GEP20012555B (bg)
GT (1) GT199800046A (bg)
HK (1) HK1023116A1 (bg)
HN (2) HN1998000036A (bg)
HR (1) HRP980107A2 (bg)
HU (1) HU225852B1 (bg)
ID (1) ID22850A (bg)
IL (1) IL131293A (bg)
IS (1) IS5163A (bg)
JO (1) JO2035B1 (bg)
MA (1) MA26473A1 (bg)
MY (1) MY118612A (bg)
NO (1) NO313383B1 (bg)
NZ (1) NZ337121A (bg)
OA (1) OA11151A (bg)
PA (1) PA8448201A1 (bg)
PE (1) PE58299A1 (bg)
PL (1) PL192864B1 (bg)
PT (1) PT966448E (bg)
SI (1) SI0966448T1 (bg)
SK (1) SK117399A3 (bg)
SV (1) SV1998000029A (bg)
TR (1) TR199902082T2 (bg)
TW (1) TW513416B (bg)
UY (1) UY24911A1 (bg)
WO (1) WO1998038174A1 (bg)
YU (1) YU40799A (bg)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6420354B1 (en) 1998-06-08 2002-07-16 Advanced Medicine, Inc. Sodium channel drugs and uses
GB9818881D0 (en) 1998-08-28 1998-10-21 Glaxo Group Ltd Compounds
GB9907965D0 (en) * 1999-04-09 1999-06-02 Glaxo Group Ltd Medical use
US6479498B1 (en) 1999-06-04 2002-11-12 Theravance, Inc. Sodium channel drugs and uses
EP1500653A1 (en) * 2000-02-16 2005-01-26 Neurogen Corporation Substituted arylpyrazines
KR20080021603A (ko) * 2000-02-16 2008-03-07 뉴로젠 코포레이션 치환된 아릴피라진
GB0010971D0 (en) * 2000-05-05 2000-06-28 Glaxo Group Ltd Process
GB0016040D0 (en) * 2000-06-29 2000-08-23 Glaxo Group Ltd Novel process for preparing crystalline particles
SE0102438D0 (sv) * 2001-07-05 2001-07-05 Astrazeneca Ab New compounds
SE0102439D0 (sv) * 2001-07-05 2001-07-05 Astrazeneca Ab New compounds
US6992087B2 (en) 2001-11-21 2006-01-31 Pfizer Inc Substituted aryl 1,4-pyrazine derivatives
MXPA04004714A (es) * 2001-11-21 2004-08-19 Upjohn Co Derivados de aril 1,4-pirazina sustituidos.
EP1458386B1 (en) * 2001-12-27 2007-04-18 Ortho-McNeil Pharmaceutical, Inc. Aroyl pyrrole heteroeryl and methanols useful for treating a central nervous system disorder
WO2003091225A1 (en) * 2002-04-26 2003-11-06 Pharmacia & Upjohn Company Substituted pyrazine derivatives
JP2006509729A (ja) 2002-08-20 2006-03-23 ニューロジェン・コーポレーション Ｃｒｆ受容体モジュレータとしての５−置換−２−アリールピラジン類
SE0203753D0 (sv) * 2002-12-17 2002-12-17 Astrazeneca Ab New compounds
SE0203754D0 (sv) * 2002-12-17 2002-12-17 Astrazeneca Ab New compounds
WO2004066987A2 (en) * 2003-01-30 2004-08-12 Dynogen Pharmaceuticals, Inc. Use of sodium channel modulators for treating gastrointestinal tract disorders
TW200510373A (en) * 2003-07-14 2005-03-16 Neurogen Corp Substituted quinolin-4-ylamine analogues
ES2567853T3 (es) 2005-01-25 2016-04-26 Synta Pharmaceuticals Corporation Compuestos contra la inflamación y utilizaciones relacionadas con el sistema inmunitario
JP2008530131A (ja) * 2005-02-15 2008-08-07 ジャズ、ファーマシューティカルズ、インコーポレイテッド 置換ピラジン化合物の徐放のための投薬形態および方法
NL2000284C2 (nl) * 2005-11-04 2007-09-28 Pfizer Ltd Pyrazine-derivaten.
EP1984339A1 (en) * 2006-01-23 2008-10-29 Pfizer Limited Pyridine derivatives as sodium channel modulators
WO2008135830A1 (en) * 2007-05-03 2008-11-13 Pfizer Limited N- [6-amino-s- (phenyl) pyrazin-2-yl] -isoxazole-4-carboxamide derivatives and related compounds as nav1.8 channel modulators for the treatment of pain
GB0800741D0 (en) 2008-01-16 2008-02-20 Univ Greenwich Cyclic triazo and diazo sodium channel blockers
GB201111712D0 (en) 2011-07-08 2011-08-24 Gosforth Ct Holdings Pty Ltd Pharmaceutical compositions
FR3001151B1 (fr) 2013-01-21 2016-04-08 Pf Medicament Association d'un bloqueur de courant sodique lent et d'un inhibiteur du courant if sinusal et les compositions pharmarceutiques la contenant
JO3517B1 (ar) * 2014-01-17 2020-07-05 Novartis Ag ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2
PL3468972T3 (pl) 2016-06-14 2020-11-16 Novartis Ag Związki i kompozycje do hamowania aktywności shp2
US11986451B1 (en) 2016-07-22 2024-05-21 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
UY37341A (es) 2016-07-22 2017-11-30 Flamel Ireland Ltd Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
CN108101857B (zh) * 2016-11-24 2021-09-03 韶远科技（上海)有限公司 制取2-氨基-3-溴-6-氯吡嗪的可放大工艺
CN107011273A (zh) * 2017-05-04 2017-08-04 无锡捷化医药科技有限公司 一种合成6‑碘‑3‑(2,3‑二氯苯基)吡嗪‑2‑胺的方法
BR112021013766A2 (pt) 2019-03-01 2021-09-21 Flamel Ireland Limited Composições de gama-hidroxibutirato com farmacocinética melhorada no estado alimentado
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal
CN115611700B (zh) * 2022-10-11 2024-06-14 辽宁东大光明化工科技有限责任公司 一种1-溴-2,5-二氯-3-氟苯的制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4402958A (en) * 1981-11-19 1983-09-06 American Cyanamid Company Novel (substituted phenyl)-1,2,4-triazolo (4,3-A)pyrazines and novel 2-hydrazino-(substituted phenyl)pyrazine intermediates
EP0288431B1 (de) 1987-04-07 1992-08-19 Ciba-Geigy Ag 3H-1,2,3-Triazolo[4,5-d]pyrimidine
JPH08238778A (ja) * 1995-03-07 1996-09-17 Brother Ind Ltd インク噴射装置の電極形成方法

Also Published As

Publication number Publication date
SK117399A3 (en) 2000-06-12
CZ311199A3 (cs) 2000-02-16
GT199800046A (es) 1999-08-20
BR9807814A (pt) 2000-02-22
TW513416B (en) 2002-12-11
IL131293A (en) 2003-07-31
MY118612A (en) 2004-12-31
DE69818643T2 (de) 2004-10-07
PA8448201A1 (es) 2000-05-24
KR100544263B1 (ko) 2006-01-23
NZ337121A (en) 2001-03-30
BG103723A (bg) 2001-05-31
JO2035B1 (en) 1999-05-15
EP0966448A1 (en) 1999-12-29
NO313383B1 (no) 2002-09-23
WO1998038174A1 (en) 1998-09-03
MA26473A1 (fr) 2004-12-20
TR199902082T2 (xx) 2000-04-21
PL192864B1 (pl) 2006-12-29
CZ295618B6 (cs) 2005-09-14
CO4950513A1 (es) 2000-09-01
PL335441A1 (en) 2000-04-25
DK0966448T3 (da) 2004-02-02
IL131293A0 (en) 2001-01-28
EE9900376A (et) 2000-04-17
HUP0001802A3 (en) 2001-07-30
AU732915B2 (en) 2001-05-03
AP9901632A0 (en) 1999-09-30
PT966448E (pt) 2004-02-27
BR9807814B1 (pt) 2009-01-13
DE69818643D1 (de) 2003-11-06
HUP0001802A2 (hu) 2001-05-28
HK1023116A1 (en) 2000-09-01
YU40799A (sh) 2001-09-28
US20020169172A1 (en) 2002-11-14
HN1998000036A (es) 1999-08-23
CA2282585A1 (en) 1998-09-03
CN1105111C (zh) 2003-04-09
IS5163A (is) 1999-08-24
EP0966448B1 (en) 2003-10-01
KR20000075859A (ko) 2000-12-26
GEP20012555B (en) 2001-10-25
SV1998000029A (es) 1998-12-11
ES2205469T3 (es) 2004-05-01
UY24911A1 (es) 2000-12-29
HU225852B1 (en) 2007-11-28
HRP980107A2 (en) 1998-12-31
CN1253551A (zh) 2000-05-17
US6599905B2 (en) 2003-07-29
CA2282585C (en) 2006-06-06
JP3369189B2 (ja) 2003-01-20
PE58299A1 (es) 1999-06-23
OA11151A (en) 2003-04-22
JP2000511203A (ja) 2000-08-29
NO994213D0 (no) 1999-08-31
HN1999000019A (es) 1999-08-23
ATE251143T1 (de) 2003-10-15
ID22850A (id) 1999-12-09
AR011174A1 (es) 2000-08-02
EA199900687A1 (ru) 2000-04-24
US6255307B1 (en) 2001-07-03
AU6823798A (en) 1998-09-18
EA002102B1 (ru) 2001-12-24
NO994213L (no) 1999-10-29

Similar Documents

Publication Publication Date Title
AP9901632A0 (en) Pyrazine compounds
ZA9810271B (en) Fused pyrazine compounds
GB9710569D0 (en) Compounds
GB9708805D0 (en) Compounds
GB9708694D0 (en) Compounds
GB9709303D0 (en) Compounds
EP0999205A4 (en) AMINOCYCLOALKAN CONNECTIONS
GB9711492D0 (en) Compounds
GB9712849D0 (en) Compounds
GB9704522D0 (en) Compounds
GB9702978D0 (en) Compounds
ZA981624B (en) Pyrazine compounds.
GB9704580D0 (en) Compounds
GB9706952D0 (en) Compounds
GB9708802D0 (en) Compounds
GB9704490D0 (en) Compounds
GB9704520D0 (en) Compounds
GB9704523D0 (en) Compounds
GB9704551D0 (en) Compounds
GB9704579D0 (en) Compounds
GB9702608D0 (en) Compounds
GB9704581D0 (en) Compounds
GB9704648D0 (en) Compounds
GB9704652D0 (en) Compounds
GB9705188D0 (en) Compounds